|Day Low/High||2.80 / 3.05|
|52 Wk Low/High||1.50 / 3.10|
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
We answer recent reader questions about three of the biotech stocks we regularly cover.
This biopharma company's Relistor drug should send revenues sharply higher this year.
This biopharma company's Relistor drug should send revenues sharply higher next year.
There are more dogs on the S&P 500 than on the Dow. Here's one example.
BDSI discontinues plan for further development resulting in an anticipated $16 million in operating plan savings in 2017 that extends cash runway
BELBUCA expected to be accretive to BDSI's 2017 net income and EPS
These small-caps are woefully undervalued after getting shellacked in October.
BUNAVAIL moved from non-formulary to preferred status
Timothy C. Tyson joins BDSI's board as an independent member with over 30 years of pharmaceutical experience
SAMHSA Reports 1,665 Clinicians Granted Waivers at the Increased Limit as of This Week
BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.
BioDelivery Sciences' (BDSI) stock rating was boosted at Janney Capital on Friday.
Top-line study results available by year-end
Investors in BioDelivery Sciences International Inc saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BDSI options chain for the new August 19th contracts and identified the following call contract of particular interest.
Don't trade the headline numbers, but cash in on those traders that do.